832740-98-4

Usage

Uses

Used in Pharmaceutical Industry:
2-(difluoromethoxy)-4-fluoroaniline is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological activities. It contributes to the development of new drugs by providing a structural foundation that can be further modified to achieve desired therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(difluoromethoxy)-4-fluoroaniline is used as a starting material for the production of pesticides and other agrochemicals. Its unique chemical structure allows for the creation of compounds that can effectively control pests and diseases in agriculture, thus enhancing crop protection and yield.
Used in Material Science:
2-(difluoromethoxy)-4-fluoroaniline is utilized in the development of new materials, particularly in the field of polymer chemistry. Its incorporation into polymer structures can lead to materials with improved properties, such as increased stability, enhanced reactivity, or altered physical characteristics, which can be beneficial in various applications.
Used in Organic Synthesis:
As an intermediate in organic synthesis, 2-(difluoromethoxy)-4-fluoroaniline plays a crucial role in the preparation of a wide range of organic compounds. Its reactivity and structural features make it a valuable building block for the synthesis of complex molecules, including those with potential applications in medicine, agriculture, and material science.

Upstream product

• 1214329-62-0 2-(difluoromethoxy)-4-fluoro-1-nitro-benzene 
• 446-36-6 5-fluoro-2-nitrophenol 

Relevant academic research and scientific papers

SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell pr

AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY

An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.

2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF

The present disclosure relates to 2-arylamino pyridine, pyrimidine, or triazine derivatives, and the preparation method and use thereof. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may act on certain mutated forms of epidermal growth fac

Amino pyrimidine compound and preparation method and application thereof

The invention relates to an amino pyrimidine compound and a preparation method and application thereof. The amino pyrimidine compound has a structure as shown in a formula I. The formula is shown in the description. The compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The invention further relates to a medicine composition comprising the compound, a preparation methodand application thereof in preparation of anti-tumor medicines.

HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.

EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF

A 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivative as represented by formula (I), and a preparation and application thereof as an EGFR inhibitor. The compound has activity of inhibiting the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, may be used to treat diseases mediated alone or in part by EGFR mutant activity, and has a wide application in drugs preventing and treating cancers, particularly non-small cell lung cancer.

Substituted indole or indole pyrimidine derivative as well as preparation method and application of substituted indole or indole pyrimidine derivative

The invention relates to a substituted indole or an indole pyrimidine derivative as well as a preparation method, a pharmaceutical composition and application of the substituted indole or the indole pyrimidine derivative, in particular relates to a compou

Pyrimidine or triazine derivative, and preparation method and use thereof

The invention relates to an arylaminopyrimidine or triazine derivative, and a preparation method, a medicinal composition and a use thereof, and concretely relates to a compound represented by formula I, or a pharmaceutically acceptable salt or a solvate thereof. In the formula I, R1 to R7, X and Y are defined in the description and claims. The invention also relates to a preparation method of the compound of formula I, the medicinal composition containing the compound, and the pharmacy use of the compound and the medicinal composition. The compound of formula I is an effective tyrosine kinase irreversible inhibitor, and especially has a strong inhibition effect on EGFR-T790M drug-resistant tumors.

EGFR (Epidermal growth factor receptor) inhibitor and preparation method and use thereof

The present invention discloses an EGFR (Epidermal growth factor receptor) inhibitor and a preparation method and use thereof. In particular, the present invention relates to compounds of N-(5-((4-((2-(alkyl-substituted sulfonyl) pyridin-3-yl) amino) pyri

Pyrimidine compound, EGFR inhibitor and application of EGFR inhibitor

The invention discloses a pyrimidine compound, an EGFR inhibitor and application of the EGFR inhibitor. The pyrimidine compound is prepared from a compound shown in the formula I or pharmaceutically acceptable salt thereof, a stereoisomer, and a solvate or prodrug. The EGFR inhibitor contains the pyrimidine compound. The pyrimidine compound can inhibit activated or resistant mutation of one or more kinds of EGFRs, can inhibit proliferation of the EGFR T790M/L858R double-mutant enzyme in the nanomolar concentration, but has a weak inhibiting effect on the wild EGFR enzyme; the pyrimidine compound is applicable to treatment of the EGFR-sensitive mutations cancer and also suitable for cases with secondary dug resistance in present EGFR-TKI treatment; meanwhile, toxic and side effects caused by inhibition on the wild EGFR are greatly reduced due to the mutation selectivity of the pyrimidine compound, and the pyrimidine compound is an ideal treatment drug for diseases caused by EGFR mutation.